EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Scope & Guideline
Elevating Drug Discovery with Premier Scientific Contributions.
Introduction
Aims and Scopes
- Drug Design and Discovery:
The journal publishes research on the design and synthesis of new drug candidates, highlighting innovative strategies for targeting various diseases, including cancer, infectious diseases, and metabolic disorders. - Structure-Activity Relationship (SAR) Studies:
A significant focus is placed on SAR studies, which investigate the relationship between chemical structure and biological activity to optimize the efficacy and selectivity of drug candidates. - Targeted Protein Degradation:
The journal features studies on PROTACs (proteolysis-targeting chimeras) and other modalities that aim to induce targeted degradation of specific proteins, offering a novel approach to cancer therapy and beyond. - Nanotechnology in Drug Delivery:
Research on nanotechnology applications in enhancing drug delivery systems, improving bioavailability, and targeting specific tissues or cells is a prominent theme. - Natural Products and Derivatives:
The journal explores the medicinal properties of natural products and their synthetic derivatives, investigating their potential as therapeutic agents and the mechanisms of action involved. - Multitarget Approaches:
There is a growing emphasis on the development of multitarget drugs that can simultaneously interact with multiple biological pathways, enhancing therapeutic efficacy and reducing resistance. - Computational Chemistry:
The integration of computational methods for predicting interactions, optimizing lead compounds, and informing synthetic strategies is a key component of the research published in the journal.
Trending and Emerging
- Targeted Protein Degradation Technologies:
The rise of PROTACs and other targeted degradation technologies is a significant trend, with increasing numbers of papers focusing on the design and application of degraders for therapeutic purposes. - Immunotherapy and Immune Modulation:
There is an emerging focus on small molecules that modulate immune responses, particularly in the context of cancer therapy, highlighting the intersection of medicinal chemistry and immunology. - Artificial Intelligence in Drug Discovery:
The integration of artificial intelligence and machine learning in drug discovery processes is gaining traction, with research exploring how these technologies can accelerate the identification of lead compounds. - Nanomedicine and Drug Delivery Systems:
Research that emphasizes the development of nanotechnology-based drug delivery systems is on the rise, focusing on improving the delivery and efficacy of therapeutics while minimizing side effects. - Multifunctional Therapeutics:
Emerging interest in multifunctional drugs that target multiple pathways or mechanisms simultaneously is evident, reflecting a shift towards more comprehensive therapeutic strategies. - Natural Product Derivatives with Enhanced Activities:
The exploration of derivatives of natural products, particularly those with optimized pharmacological profiles, is increasingly common as researchers seek to harness the therapeutic potential of these compounds. - Research on Metabolic Disorders:
A growing number of studies are addressing metabolic disorders, including diabetes and obesity, with a focus on discovering new therapeutic agents that can effectively manage these conditions.
Declining or Waning
- Traditional Small Molecule Inhibitors:
Research focusing solely on traditional small molecule inhibitors without integrating newer methodologies, such as PROTACs or nanotechnology, seems to be less frequent as the field evolves towards more innovative therapeutic approaches. - Single Target Drug Development:
There is a noticeable decline in publications centered around single-target drug development. The trend is shifting towards multitarget strategies that address the complexity of diseases, particularly in cancer and chronic conditions. - Synthetic Pathway Optimization:
Publications dedicated exclusively to optimizing synthetic pathways without a strong emphasis on biological evaluation are becoming less common, as researchers increasingly prioritize bioactivity and therapeutic relevance in their studies. - Basic Pharmacology Studies:
Basic pharmacological studies that do not explore clinical implications or translational potential are appearing less frequently, reflecting a growing expectation for research to connect laboratory findings with clinical applications.
Similar Journals
ACS Medicinal Chemistry Letters
Advancing medicinal breakthroughs through innovative research.ACS Medicinal Chemistry Letters, published by the American Chemical Society, is a distinguished journal dedicated to advancing the field of medicinal chemistry. With impressive rankings in the 2023 category quartiles—Q1 in Drug Discovery and Organic Chemistry as well as Q2 in Biochemistry—this journal serves as a vital platform for researchers seeking to publish innovative findings and methodologies in drug development and therapeutic advancements. The journal's notable impact is reflected in its Scopus rankings, where it stands at #43 in Organic Chemistry and #45 in Drug Discovery. Although it does not currently offer open access, the contributions published from 2010 to 2024 provide a wealth of knowledge critical to both academia and industry. As a key resource for students, professionals, and researchers in the fields of chemistry and pharmacology, ACS Medicinal Chemistry Letters plays an essential role in shaping the future of medicinal therapeutics.
ACS Bio & Med Chem Au
Exploring breakthroughs in pharmaceutical sciences and molecular biology.ACS Bio & Med Chem Au, published by the esteemed American Chemical Society, stands at the forefront of interdisciplinary research within the realms of biochemistry, drug discovery, pharmaceutical sciences, and molecular biology. With an impressive Impact Factor indicative of its rigorous academic standards and significant contributions to the field, this open-access journal is committed to disseminating high-quality research that drives innovation and advancements in biosciences and medicinal chemistry. Since its inception in 2021, the journal has rapidly earned recognition, achieving a commendable Q1 ranking in multiple categories, including Biochemistry, Drug Discovery, and Pharmaceutical Science, while also making strides in Molecular Biology. Researchers, professionals, and students alike can explore pioneering studies that bridge gaps between laboratory research and clinical applications, fostering collaborative efforts towards novel therapeutic strategies. With a focus on enhancing accessibility and engagement within the scientific community, ACS Bio & Med Chem Au is poised to impact the future of biomedical research significantly.
NATURAL PRODUCT RESEARCH
Illuminating the Path to Natural Product BreakthroughsNATURAL PRODUCT RESEARCH is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of natural product science through the dissemination of high-quality research. Established in 2003, this journal serves as a pivotal platform for scholars in Analytical Chemistry, Biochemistry, Organic Chemistry, and Plant Science, boasting an impressive categorization including Q2 in Plant Science and Q3 in the other disciplines for 2023. With a current Scopus ranking that highlights its significance within various scientific communities, NATURAL PRODUCT RESEARCH reflects the complexities and innovations associated with natural compounds and their applications. Researchers, professionals, and students will find valuable insights and breakthroughs that contribute to the understanding of bioactive compounds and their roles in health and environmental sustainability. Access options are available, ensuring that the latest findings are accessible to a global audience. As this journal continues to publish until 2024, it remains an essential resource for those at the forefront of natural product research.
Research Journal of Pharmacognosy
Unlocking the potential of nature for future pharmacological advancements.Research Journal of Pharmacognosy, published by the Iranian Society of Pharmacognosy, is a pioneering forum for the dissemination of research in the field of pharmacognosy and its related disciplines. Founded in 2014 as an Open Access journal, it aims to provide swift and free access to high-quality research articles, fostering collaboration and innovation among researchers, professionals, and students. Operating from Tehran, Iran, this journal addresses a wide range of topics including complementary and alternative medicine, drug discovery, and organic chemistry, making it an invaluable resource for those researching the extraction, characterization, and application of naturally derived compounds. The journal holds a Category Quartile ranking of Q3 in Complementary and Alternative Medicine and Q4 in both Drug Discovery and Organic Chemistry for the year 2023, which underscores its growing influence within the scientific community. By serving as a platform for current advances and thought leadership in pharmacognosy, the Research Journal of Pharmacognosy plays a crucial role in bridging the gap between traditional practices and modern pharmacological applications.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Transforming Challenges into Solutions in Medicinal ChemistryCURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.
Acta Pharmaceutica Sinica B
Championing Excellence in Pharmaceutical ResearchActa Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.
Future Medicinal Chemistry
Advancing the frontiers of drug discovery.Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.
ChemMedChem
Innovating drug discovery through interdisciplinary collaboration.ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.
CURRENT DRUG TARGETS
Advancing the Frontiers of Pharmacological ResearchCURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.
Anti-Cancer Agents in Medicinal Chemistry
Bridging medicinal chemistry and clinical applications for a cancer-free future.Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.